Published in J Invest Dermatol on March 10, 2011
Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer (2013) 2.14
Multivariable analysis. J Invest Dermatol (2014) 0.91
Statin use is not associated with reduced risk of skin cancer: a meta-analysis. Br J Cancer (2013) 0.89
Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control (2012) 0.88
Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis (2011) 0.84
Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. PLoS One (2014) 0.82
Screening and prevention measures for melanoma: is there a survival advantage? Curr Oncol Rep (2012) 0.81
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer (2012) 0.80
The search for a chemoprevention agent effective against melanoma: considerations and challenges. J Invest Dermatol (2011) 0.77
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn's hypothesis in the human melanoma system. Oncoimmunology (2012) 0.77
Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Phila) (2014) 0.77
Wnt/β-Catenin Signaling Pathway in Skin Carcinogenesis and Therapy. Biomed Res Int (2015) 0.77
Chemoprevention of melanoma. Adv Pharmacol (2012) 0.76
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. Front Immunol (2015) 0.76
Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients. BMC Cancer (2014) 0.76
Aspirin for the primary prevention of skin cancer: A meta-analysis. Oncol Lett (2015) 0.75
Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin. Drug Des Devel Ther (2013) 0.75
Do nonsteroidal anti-inflammatory drugs prevent melanoma? J Invest Dermatol (2011) 0.75
Aspirin in dermatology: Revisited. Indian Dermatol Online J (2016) 0.75
Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. Eur J Clin Pharmacol (2013) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc (2004) 3.40
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol (2013) 2.71
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol (2007) 2.59
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol (2010) 2.18
Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology (2009) 2.08
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Dermatol Surg (2011) 2.03
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol (2012) 1.93
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol (2007) 1.83
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (2005) 1.78
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Heat conduction from the exceedingly hot fiber tip contributes to the endovenous laser ablation of varicose veins. Lasers Med Sci (2009) 1.69
Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med (2008) 1.69
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study. Arch Dermatol (2011) 1.66
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) 1.57
Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57
The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol (2003) 1.53
Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg (2008) 1.51
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Proof-of-principle study of steam ablation as novel thermal therapy for saphenous varicose veins. J Vasc Surg (2011) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol (2011) 1.44
Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Melanoma Res (2009) 1.43
Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol (2010) 1.42
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology (2009) 1.42
[Basal cell carcinoma: often more than one]. Ned Tijdschr Geneeskd (2011) 1.39
Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol (2013) 1.39
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res (2006) 1.35
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol (2008) 1.33
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res (2007) 1.31
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther (2004) 1.29
Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) (2014) 1.29
Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24
Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol (2010) 1.24
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem (2007) 1.21
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg (2009) 1.17
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol (2005) 1.16
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology (2007) 1.13
Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res (2009) 1.12
Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol (2009) 1.11
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther (2010) 1.10
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol (2009) 1.10
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
Bullous pemphigoid therapy -- think globally, act locally. N Engl J Med (2002) 1.09
Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol (2012) 1.07
Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res (2008) 1.07
Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol (2011) 1.06
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res (2007) 1.03
BRAF mutations in metanephric adenoma of the kidney. Eur Urol (2012) 1.02
Scanning laser ophthalmoscope imaging stabilized microperimetry in dry age-related macular degeneration. Retina (2011) 1.02
Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer (2013) 1.02
Risk factors for single and multiple basal cell carcinomas. Arch Dermatol (2010) 1.01
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol (2009) 1.01
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol (2003) 1.00
Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol (2013) 0.99
Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol (2009) 0.98
Telaprevir-related dermatitis. JAMA Dermatol (2013) 0.98